



2500us1p.ST25.txt
SEQUENCE LISTING

BEST AVAILABLE COPY

<110> SAIKAWA, Akira
IGARI, Yasutaka
YAMAMOTO, Yoshio
HATA, Yoshio

<120> Sustained-Release Composition, Methods of its Preparation and Use
Thereof

<130> 2500 US1P

<140> 10/799,320
<141> 2004-03-12

<150> US 09/582,926
<151> 2000-07-05

<150> PCT/JP99/00086
<151> 1999-01-13

<150> JP 10-6412
<151> 1998-01-16

<160> 5

<170> PatentIn version 3.2

<210> 1
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> LH-RH peptide derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 5-oxo-Pro carboxy terminal

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Y=DLeu, DAla, DTrp, DSer(tbut), D2NaI or DHis(ImBzl)

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Z=Gly-NH2 or NH-C2H5 amino terminal

<400> 1

Pro His Trp Ser Tyr Xaa Leu Arg Pro Xaa
1 5 10

<210> 2
<211> 11
<212> PRT
<213> Artificial Sequence

2500us1p.ST25.txt

<220>

<223> LH-RH antagonist derivative/analog

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X=N(4H2-furoyl)Gly or NAC

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> D2NaI

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> D4C1Phe

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> D3PaI

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> A=NMeTyr, Tyr, Aph(Atz) and NMeAph(Atz)

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> B=DLys(Nic), DCit, DLys(AzaglyNic), DLys(AzaglyFur), DhArg(Et2), Daph(Atz), DhCi.

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> C=Lys(Nisp), Arg, hArg(Et2).

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> DA1aNH2

<400> 2

Xaa	Xaa	Xaa	Xaa	Ser	Xaa	Xaa	Leu	Xaa	Pro	Xaa
1				5					10	

<210> 3

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> LH-RH peptide derivative/analog

<220>

<221> MISC_FEATURE

<222> (1)..(1)

2500us1p.ST25.txt

<223> 5-oxo-Pro carboxy terminal

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> DLeu

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> Pro-NH-C2H5 amino terminal

<400> 3

Pro His Trp Ser Tyr Xaa Arg Pro

1

5

<210> 4

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> LH-RH peptide derivative/analog

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> N-(S)-tetrahydrofur-2-oyl-Gly

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> D2NaI

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> D4C1Phe

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> D3PaI

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> NMeTyr

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> DLys(Nic)

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> Lys(Nisp)

<220>

2500us1p.ST25.txt

<221> MISC_FEATURE
<222> (11)..(11)
<223> DA1aNH2

<400> 4

Gly Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1 5 10

<210> 5
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> LH-RH peptide derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 5-oxo-Pro carboxy terminal

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> DLeu

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Pro-NH-C2H5 amino terminal

<400> 5

Pro His Trp Ser Tyr Xaa Leu Arg Pro
1 5